A randomized controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones and liver markers in women with polycystic ovary syndrome
Javed, Zeeshan; Papageorgiou, Maria; Deshmukh, Harshal; Kilpatrick, Eric; Mann, Vincent; Corless, Lynsey; Abouda, George; Rigby, Alan S.; Atkin, Stephen; Sathyapalan, Thozhukat
Alan S. Rigby
Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4nmol/L, FU: 90.4±19.5nmol/L vs. placebo, baseline: 30.9 ± 11.1nmol/L, FU: 47.6 ± 20.5nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.
|Journal Article Type||Article|
|Publication Date||Jan 17, 2019|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Javed, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E., Mann, V., Corless, L., …Sathyapalan, T. (2019). A randomized controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1), 188. https://doi.org/10.3390/nu11010188|
|Keywords||Polycystic ovary syndrome; Vitamin D; Liver markers; Cardiovascular risk factors; Hormones|
© 2018 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
You might also like
Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women